225 related articles for article (PubMed ID: 22178753)
1. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
Dekeyne A; Brocco M; Loiseau F; Gobert A; Rivet JM; Di Cara B; Cremers TI; Flik G; Fone KC; Watson DJ; Papp M; Sharp T; Serres F; Cespuglio R; Olivier B; Chan JS; Lavielle G; Millan MJ
J Pharmacol Exp Ther; 2012 Mar; 340(3):765-80. PubMed ID: 22178753
[TBL] [Abstract][Full Text] [Related]
2. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
3. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
4. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ
Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
7. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
Millan MJ; Gobert A; Roux S; Porsolt R; Meneses A; Carli M; Di Cara B; Jaffard R; Rivet JM; Lestage P; Mocaer E; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Oct; 311(1):190-203. PubMed ID: 15146031
[TBL] [Abstract][Full Text] [Related]
8. On the mechanism of antidepressant-like action of berberine chloride.
Kulkarni SK; Dhir A
Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
[TBL] [Abstract][Full Text] [Related]
9. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
10. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
11. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
[TBL] [Abstract][Full Text] [Related]
12. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.
Deltheil T; Guiard BP; Cerdan J; David DJ; Tanaka KF; Repérant C; Guilloux JP; Coudoré F; Hen R; Gardier AM
Neuropharmacology; 2008 Nov; 55(6):1006-14. PubMed ID: 18761360
[TBL] [Abstract][Full Text] [Related]
13. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A
J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458
[TBL] [Abstract][Full Text] [Related]
14. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats.
Millan MJ; Gobert A; Panayi F; Rivet JM; Dekeyne A; Brocco M; Ortuno JC; Di Cara B
Int J Neuropsychopharmacol; 2008 Dec; 11(8):1105-22. PubMed ID: 18466669
[TBL] [Abstract][Full Text] [Related]
15. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
Consoli D; Leggio GM; Mazzola C; Micale V; Drago F
Eur J Pharmacol; 2007 Nov; 573(1-3):139-47. PubMed ID: 17669397
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors.
Cryan JF; Lucki I
J Pharmacol Exp Ther; 2000 Dec; 295(3):1120-6. PubMed ID: 11082448
[TBL] [Abstract][Full Text] [Related]
17. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
18. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
Dhir A; Kulkarni SK
Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
[TBL] [Abstract][Full Text] [Related]
19. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
[TBL] [Abstract][Full Text] [Related]
20. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes.
Yonezawa A; Yoshizumi M; Ebiko M; Ise SN; Watanabe C; Mizoguchi H; Kimura Y; Sakurada S
Pharmacol Biochem Behav; 2008 Feb; 88(4):367-73. PubMed ID: 17936345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
